Liver transplant drug trial halted early – only 6 patients enrolled
NCT ID NCT05514119
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the drug fenofibrate could prevent a type of bile duct damage called ischemic cholangiopathy in people who received a liver from a donor after circulatory death. Only 6 participants were enrolled before the trial was terminated early. The main goal was to see if patients could tolerate the medication without serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fenofibrate (Lofibra), a medication taken as a 160 mg pill once daily for 12 weeks
What this could lead to
If it worked, fenofibrate could help prevent bile duct damage in people who receive a liver from a donor after circulatory death, improving transplant success.
What could go wrong
The trial was terminated early and only enrolled 6 people, so results are very limited. Fenofibrate may cause side effects like kidney issues or rejection, and its benefit is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Arizona
Phoenix, Arizona, 85254, United States